secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keenova Therapeutics plc (—)
CIK:        0001567892
Form:       8-K
Filed at:   2025-08-01T23:59:59+00:00
Accession:  0001104659-25-072891
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 1.02, 2.01, 2.02, 7.01, 2.03, 2.04, 3.03, 5.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mallinckrodt completes acquisition of Endo; new $1.35B credit facilities
------------------------------------------------------------------------

- Acquisition closed July 31, 2025; Endo shareholders received $1.31 cash + 0.2575 Mallinckrodt shares per share.
- New $1.35B senior secured facilities: $1.2B term loan (fully drawn Aug 1) and $150M revolver; maturity July 31, 2030.
- Existing debt refinanced: ~$385.5M term loans and ~$477.2M notes repaid; make-whole premiums of ~$10.6M and ~$13.7M paid.
- Board reconstituted: three directors resigned; four Endo directors (Efron, Hirsch, Langlois, Yoskowitz) and Leslie Donato appointed.
- Post-merger committees set: Efron Chair; Langlois chairs Audit; Bisaro, Dorton, Zinman on committees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1567892/000110465925072891/0001104659-25-072891-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1567892/000110465925072891/tm2522037d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-072891

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer